Subtopic Deep Dive
Pathophysiology of Microscopic Colitis
Research Guide
What is Pathophysiology of Microscopic Colitis?
Pathophysiology of microscopic colitis encompasses immune dysregulation, epithelial barrier dysfunction, and microbial dysbiosis driving chronic colonic inflammation in collagenous and lymphocytic forms.
Microscopic colitis features normal endoscopy with histological inflammation, including subepithelial collagen bands in collagenous colitis and intraepithelial lymphocytes in lymphocytic colitis. Key studies identify extracellular matrix alterations (Aigner et al., 1997, 146 citations) and cytokine-mediated motility changes (Akiho, 2011, 109 citations). Over 20 papers from 1996-2022 detail genetic, proteomic, and microbiome mechanisms.
Why It Matters
Understanding pathophysiology enables biomarkers for diagnosis and therapies targeting immune pathways beyond budesonide. Miehlke et al. (2020, 197 citations) outline guidelines linking histology to immune dysregulation for personalized treatment. Yen et al. (2011, 119 citations) show smoking doubles risk via barrier disruption, guiding prevention. Wildt et al. (2006, 101 citations) demonstrate probiotics reduce symptoms by modulating microbiota, impacting 50,000+ annual US cases.
Key Research Challenges
Immune Dysregulation Mechanisms
T-cell infiltration and cytokine profiles remain incompletely mapped in collagenous vs lymphocytic colitis. Akiho (2011) links cytokines to motility changes, but causal pathways need clarification. Dougan (2017, 163 citations) highlights checkpoint parallels untested in colitis.
Epithelial Barrier Defects
Collagen deposition disrupts permeability, but triggers are unclear. Aigner et al. (1997) detail matrix gene expression changes without functional models. NSAID and smoking links (Yen et al., 2011) suggest multifactorial injury.
Microbiome-Host Interactions
Dysbiosis role is emerging but lacks causal evidence in humans. Whitfield-Cargile et al. (2016, 133 citations) show indole protects in NSAID models, while Wildt et al. (2006) report probiotic benefits needing mechanistic validation.
Essential Papers
Collagenous colitis: a retrospective study of clinical presentation and treatment in 163 patients.
Johan Bohr, Curt Tysk, S. Eriksson et al. · 1996 · Gut · 560 citations
BACKGROUND: Data on collagenous colitis have been based on a limited number of patients. AIMS: To obtain more information on this disease from a register set up at Orebro Medical Center Hospital. P...
European guidelines on microscopic colitis: United European Gastroenterology and European Microscopic Colitis Group statements and recommendations
Stephan Miehlke, Danila Guagnozzi, Yamile Zabana et al. · 2020 · United European Gastroenterology Journal · 197 citations
Abstract Introduction Microscopic colitis is a chronic inflammatory bowel disease characterised by normal or almost normal endoscopic appearance of the colon, chronic watery, nonbloody diarrhoea an...
Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract
Michael Dougan · 2017 · Frontiers in Immunology · 163 citations
Monoclonal antibodies targeting the regulatory immune "checkpoint" receptors CTLA-4, PD-1, and PD-L1 are now standard therapy for diverse malignancies including melanoma, lung cancer, and renal cel...
Extracellular matrix composition and gene expression in collagenous colitis
Thomas Aigner, Daniel Neureiter, S. Müller et al. · 1997 · Gastroenterology · 146 citations
The microbiota-derived metabolite indole decreases mucosal inflammation and injury in a murine model of NSAID enteropathy
Canaan Whitfield-Cargile, Noah D. Cohen, Robert S. Chapkin et al. · 2016 · Gut Microbes · 133 citations
Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most frequently used classes of medications in the world. Unfortunately, NSAIDs induce an enteropathy associated with high morbidity an...
Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility
Edoardo Savarino, Fabiana Zingone, Brigida Barberio et al. · 2022 · United European Gastroenterology Journal · 131 citations
Abstract Irritable bowel syndrome with diarrhoea (IBS‐D) and functional diarrhoea (FDr) are the two major functional bowel disorders characterized by diarrhoea. In spite of their high prevalence, I...
Current and past cigarette smoking significantly increase risk for microscopic colitis
Eugene F. Yen, Bhupesh Pokhrel, Hongyan Du et al. · 2011 · Inflammatory Bowel Diseases · 119 citations
In our study population, cigarette smoking is a risk factor for the development of both forms of microscopic colitis. There were no significant differences between LC and CC, and current smoking an...
Reading Guide
Foundational Papers
Start with Bohr et al. (1996, 560 citations) for clinical context, then Aigner et al. (1997, 146 citations) for matrix pathophysiology core.
Recent Advances
Study Miehlke et al. (2020, 197 citations) guidelines and Whitfield-Cargile et al. (2016, 133 citations) for microbiota advances.
Core Methods
Histological collagen banding quantification, cytokine ELISA, 16S rRNA microbiome profiling, and smoking risk epidemiology (Yen et al., 2011).
How PapersFlow Helps You Research Pathophysiology of Microscopic Colitis
Discover & Search
Research Agent uses searchPapers('pathophysiology microscopic colitis immune dysregulation') to retrieve Miehlke et al. (2020), then citationGraph reveals Aigner et al. (1997) as foundational, and findSimilarPapers uncovers smoking risks from Yen et al. (2011). exaSearch('collagenous colitis matrix gene expression') surfaces 50+ related works.
Analyze & Verify
Analysis Agent applies readPaperContent on Aigner et al. (1997) to extract matrix protein data, verifyResponse with CoVe checks claims against Miehlke guidelines (2020), and runPythonAnalysis plots cytokine levels from Akiho (2011) abstracts using pandas for statistical trends. GRADE grading scores evidence as moderate for immune mechanisms.
Synthesize & Write
Synthesis Agent detects gaps in microbiome causality from Wildt et al. (2006) vs Whitfield-Cargile (2016), flags contradictions in smoking effects. Writing Agent uses latexEditText for pathophysiology review, latexSyncCitations integrates 20 papers, latexCompile generates PDF, exportMermaid diagrams T-cell infiltration pathways.
Use Cases
"Extract microbiome data from microscopic colitis probiotic trials"
Research Agent → searchPapers('probiotics collagenous colitis') → Analysis Agent → readPaperContent(Wildt 2006) → runPythonAnalysis(pandas meta-analysis of symptom scores) → CSV export of effect sizes.
"Draft LaTeX review on collagen deposition in collagenous colitis"
Synthesis Agent → gap detection(Aigner 1997 + Miehlke 2020) → Writing Agent → latexEditText(structured sections) → latexSyncCitations(15 refs) → latexCompile(PDF review).
"Find code for colitis cytokine network analysis"
Research Agent → paperExtractUrls(cytokine papers) → Code Discovery → paperFindGithubRepo → githubRepoInspect → runPythonAnalysis(adapt network model to Akiho 2011 data).
Automated Workflows
Deep Research workflow scans 50+ papers via searchPapers on 'microscopic colitis pathophysiology', structures report with GRADE-scored immune mechanisms from Miehlke (2020). DeepScan applies 7-step CoVe to verify barrier defect claims in Aigner (1997), outputting verified summary. Theorizer generates hypotheses linking smoking (Yen 2011) to microbiota shifts (Whitfield-Cargile 2016).
Frequently Asked Questions
What defines pathophysiology of microscopic colitis?
Immune dysregulation with T-cell infiltration, barrier dysfunction via collagen deposition, and microbial influences underlie normal-appearing endoscopic inflammation (Miehlke et al., 2020).
What methods study microscopic colitis mechanisms?
Histology, proteomics for matrix changes (Aigner et al., 1997), microbiome sequencing, and cytokine assays assess motility impacts (Akiho, 2011).
What are key papers on this topic?
Bohr et al. (1996, 560 citations) on clinical features; Aigner et al. (1997, 146 citations) on matrix; Miehlke et al. (2020, 197 citations) on guidelines.
What open problems persist?
Causal microbiome roles, genetic predispositions, and targeted immune therapies lack validation beyond observational data (Wildt et al., 2006).
Research Microscopic Colitis with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Pathophysiology of Microscopic Colitis with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Microscopic Colitis Research Guide